A Phase 1-3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2) (ALLOHA-2)

A Phase 1-3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.

Study Overview

• Status: Recruiting
• Conditions: AML; MDS
• Intervention / Treatment: Other: Control; Drug: TSC-101

Detailed Description

This is a multicenter, genetically-randomized, controlled, Phase 3 study designed to evaluate the efficacy and safety of TSC-101 in adult participants with AML or MDS undergoing allogeneic peripheral blood stem cell transplantation following reduced-intensity conditioning (RIC). TSC-101 is a donor-derived, genetically engineered T-cell therapy designed to express a therapeutic T-cell receptor recognizing the HA-2 minor histocompatibility antigen presented by HLA-A*02:01. The study is intended to evaluate whether administration of TSC-101 following transplantation can improve clinical outcomes compared with standard transplantation alone.

Eligible participants are adults with AML or MDS who are candidates for first allogeneic HCT using a haploidentical or mismatched unrelated donor and post-transplant. Participants assigned to the treatment arm must be HLA-A*02:01 positive, express HA-2, and have a study-eligible HLA-A*02-negative donor. Participants who are HLA-A*02:01 positive but do not have a study-eligible donor, as well as participants who are HLA-A*02:01 negative, may be assigned to the control arm.

Approximately 310 participants will be enrolled, with approximately 155 participants in each study arm. Participants assigned to the treatment arm will receive two infusions of TSC-101 following recovery after transplantation. The first infusion is planned approximately 21 days after HCT (Day +14 to Day +35), and the second infusion is planned approximately 40 days after the first infusion (40 to 68 days after Infusion 1).

All participants will receive SOC transplantation procedures, including one of several protocol-specified RIC regimens followed by peripheral blood stem cell transplantation and post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GvHD) prophylaxis.

Safety will be monitored through ongoing review of adverse events, laboratory assessments, and clinical evaluations. An independent Data Safety Monitoring Board (DSMB) will periodically review safety data and study conduct and make recommendations regarding continuation, modification, or termination of the study.

This is an event-driven study. Participants will be followed for up to 3 years after HCT. Participants who receive at least one TSC-101 infusion will subsequently participate in a separate long-term follow-up study for up to 15 years following their final TSC-101 infusion to monitor long-term safety and survival outcomes.

• Study Type: Interventional
• Enrollment (Estimated): 310
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Marlyane Motta; Phone Number: (857) 399-9887; Email: mmotta@tscan.com

Study Locations

• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Not yet recruiting
      • Banner Health - MD Anderson Cancer Center
      • Principal Investigator: Yazan Samhouri, MD
    • Scottsdale, Arizona, United States, 85258
      • Not yet recruiting
      • Honor Health Cancer Transplant Institute
      • Principal Investigator: Abdullah Ladha, MD
  • California
    • Duarte, California, United States, 91010
      • Recruiting
      • City of Hope
      • Principal Investigator: Monzr M Al Malki, MD
    • Stanford, California, United States, 94305
      • Not yet recruiting
      • Stanford - School of Medicine
      • Principal Investigator: Hany Elmariah, MD
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Recruiting
      • University of Colorado - Anschutz Cancer Center
      • Principal Investigator: Mathew Angelos, MD
    • Denver, Colorado, United States, 80218
      • Recruiting
      • SCRI - Colorado Blood Cancer Institute
      • Principal Investigator: Marcello Rotta, MD
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Recruiting
      • Yale
      • Principal Investigator: Lohith Gowda, MD
  • Florida
    • Hollywood, Florida, United States, 33021
      • Recruiting
      • Memorial Cancer Institute
      • Principal Investigator: Hugo Fernandez, MD
    • Tampa, Florida, United States, 33612
      • Recruiting
      • Moffitt Cancer Institute
      • Principal Investigator: Nelli Bejanyan, MD
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Recruiting
      • Northside Hospital
      • Principal Investigator: Melholm Sohl, MD
  • Illinois
    • Chicago, Illinois, United States, 60607
      • Not yet recruiting
      • University of Chicago
      • Principal Investigator: Gregory Roloff, MD
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • Not yet recruiting
      • The University of Kansas Cancer Center
      • Principal Investigator: Rajat Bansal, MD
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Recruiting
      • Johns Hopkins University
      • Principal Investigator: Tania Jain, MD
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Recruiting
      • Massachusetts General Hospital
      • Principal Investigator: Yi-Bin Chen, MD
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Dana-Farber Cancer Institute - Hematology/Oncology
      • Principal Investigator: Mahasweta Gooptu, MD
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Karmanos Cancer Institute
      • Principal Investigator: Joseph Uberti, MD
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Recruiting
      • Hackensack University Medical Center
      • Principal Investigator: Michele Donato, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Subject Inclusion Criteria:

1. Patient aged ≥ 18 years at the time of signing informed consent.
2. Karnofsky Performance Status (KPS) ≥50 at the time of the screening visit.

3. Undergoing first allo-HCT with a diagnosis of:

   • AML with bone marrow blasts < 5%, absence of circulating blasts, and absence of extramedullary disease.
   • MDS
4. Must express HLA-A*02:01 as determined by pre-transplant institutional SOC work-up to be eligible for the treatment arm.
5. Must have the HA-2 positive genotype to be eligible for the treatment arm.

6. Undergoing RIC HCT using a haplo donor or MMUD.

   • Donors for treatment-arm subjects must be HLA-A*02-negative.
   • Donors for control-arm subjects do not have to be HLA-A*02-negative.
7. Undergoing use of PTCy for GvHD prophylaxis at standard doses.
8. Use of peripheral blood stem cell source.
9. Organ function parameters for transplant eligibility are met per institutional standards. Where organ function may fall outside of institutional standard for transplant, and patient is still proceeding to transplant, the case should be reviewed and approved by the MedicalMonitor.
10. Patient or legally authorized representative (LAR) capable of giving signed informed consent and willingness to comply with the requirements and restrictions listed in the informed consent form (ICF) and clinical protocol.
11. Agrees to participate in long-term follow-up (LTFU) for up to 15 years post the final infusion of TSC-101 if they receive a TSC-101 infusion.

12. Contraceptive use by male and female subjects must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. At a minimum:

    • A male subject must agree to use a highly effective contraceptive during the intervention period and for at least 12 months after the last TSC-101 infusion and refrain from donating sperm during this period.

    • A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

      • Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 OR
      • A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the intervention period and for at least 12 months after the last TSC-101 infusion.

Subject Exclusion Criteria:

Patients are excluded from the study if any of the following criteria apply:

1. Potential treatment-arm patient is positive for HLA-A*02:07.

   • Patients considered for the control arm can be positive for HLA-A*02 (including HLA-A*02:07).

2. For patients with AML: those in third complete remission (CR3) or greater, partial remission, or with active AML disease.
3. If patient required hemodialysis or mechanical ventilation within 3 months prior to enrollment, circumstances must be discussed with the Sponsor Medical Monitor.
4. Prior allo-HCT.
5. Use of anti-thymocyte globulin (ATG), alemtuzumab, or other in vivo or ex vivo T-cell depleting agents from Day -14 (pre-HCT) through end of study (EOS). Corticosteroids and maintenance therapies may be allowed under certain circumstances.
6. History of hypersensitivity to murine proteins.
7. Enrollment in a concomitant study with an investigational agent. All other concomitant trials must be reviewed and approved by the Medical Monitor.

8. Cardiac disease, defined as:

   • Uncontrolled or symptomatic angina within the past 3 months.
   • History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.
   • Myocardial infarction < 6 months from study entry.
   • Uncontrolled or symptomatic congestive heart failure.
   • Cardiac ejection fraction at rest of less than 40% or shortening fraction of less than 22% by echocardiogram or radionuclide scan (multi-gated acquisition [MUGA] scan).

9. Medical or psychological conditions that would make the patient an unsuitable candidate for participation on a cell therapy trial, including active central nervous system disease and/or prior malignancy(s) within the last 3 years, except:

   • Lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ will be allowed. Cancer treated with curative intent ≥ 3 years previously will be allowed

Donor Inclusion Criteria:

1. Male or female ≥ 50 kg and aged ≥ 16 years at the time of signing informed consent who meet the criteria to donate as per the institutional SOC.
2. Capable of giving signed informed consent, or assent/parental consent per institutional SOC, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
3. For treatment-arm donors: able to undergo peripheral blood stem cell (PBSC) collection and at least 2 rounds of leukapheresis (for both TSC-101 manufacturing and the stem cell collection for HCT).
4. For treatment-arm donors: negative for all HLA-A*02 alleles • Donors for control-arm subjects do not have to be negative for HLA-A*02 alleles.

Donor Exclusion Criteria:

1. Donors for control-arm subjects who do not meet institutional standards for donor selection.

2. Donors for treatment-arm subjects:

   • Who test positive for any of the following: human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, seropositive or with active hepatitis B or hepatitis C virus infection, syphilis, West Nile virus through central lab testing. Donors who screen positive for Creutzfeldt Jakob disease using donor history questionnaires will also be excluded. Donors with evidence of past cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infections will be allowed.
   • For whom the treating Investigator deems subject level donor-specific HLA antibodies are high enough to warrant treatment with desensitization protocols.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm (TSC-101); Participants who are HLA-A*02:01-positive and undergoing reduced intensity conditioning hematopoietic stem cell transplantation using allogeneic HLA-A*02 negative donors.	Drug: TSC-101; SOC + TSC-101
Active Comparator: Control Arm (Standard of Care); Participants who are not HLA-A*02:01-positive, HA-2-positive, or who are treatment-arm eligible but for whom an HLA-A*02-negative donor cannot be identified, will be assigned to the control arm and receive allo-HCT alone.; Participants who are HLA-A*02:01 negative, will be assigned to the control arm and receive allo-HCT alone.	Other: Control; SOC alone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Relapse-free survival (RFS)	To determine the efficacy of TSC-101 by assessing relapse-free survival (RFS)	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-free survival (EFS)	To determine the efficacy of TSC-101 by event-free survival (EFS)	3 years
Overall survival (OS)	To determine the efficacy of TSC-101 by overall survival (OS)	3 years
Time to relapse (TTR)	To determine the efficacy of TSC-101 by assessing time to relapse (TTR)	3 years
Changes over time in Quality of Life Score - EQ-5D-5L	To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of EQ-5D-5L	3 years
Changes over time in Quality of Life Score - FACT-Leu	To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-Leu	3 years
Changes over Quality of Life Scores in FACT-BMT	To determine the efficacy of TSC-101 by tracking changes over time in quality of life scores of FACT-BMT	3 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of treatment-emergent adverse events	To determine the safety and tolerability of TSC-101 through incidence and severity of treatment-emergent adverse events	3 years
TSC-101 Expansion and Persistence	To characterize the in vivo cellular pharmacokinetic (PK) profile of TSC-101 by analysis of peak persistence and other relevant PK parameters of TSC-101cells	3 years
Non-Relapse Mortality	Assess non-relapse mortality (NRM) of TSC-101	3 years
Overall Response Rates	To determine the efficacy of TSC-101 retreatment infusion through: overall response rates assessed by the Investigator.	3 years
MRD-negative CR in bone marrow	To determine the efficacy of TSC-101 retreatment infusion though analysis of the proportion of subjects achieving MRD-negative CR in bone marrow	3 years
Full Donor Chimerism	To determine the efficacy of TSC-101 retreatment infusion by analyzing the proportion of subjects achieving full donor chimerism.	3 years
Duration of response (DoR)	To determine the efficacy of TSC-101 retreatment infusion by Duration of response (DoR)	3 years
EFS post-retreatment	To determine the efficacy of TSC-101 retreatment infusion by EFS post-retreatment	3 years
OS post-retreatment	To determine the efficacy of TSC-101 retreatment infusion by OS post-retreatment	3 years
MRD positivity	To determine presence of and changes in minimal residual disease (MRD) by rates of MRD positivity pre-and post-HCT	3 years
Post-HCT conversion of MRD	To determine presence of and changes in minimal residual disease (MRD) by proportion of subjects with post-HCT conversion of MRD.	3 years
Changes in Donor Chimerism	To determine presence and changes of mixed chimerism and association with relapses by analyzing changes in donor chimerism over time.	3 years
Predictive Value of Donor Chimerism	To determine presence and changes of mixed chimerism and association with relapses through predictive value of mixed or full donor chimerism for relapse.	3 years
Healthcare Utilization post-HCT	To determine the healthcare utilization post-HCT by hospitalization days through one-year post-HCT.	1 year

Collaborators and Investigators

• Sponsor: TScan Therapeutics, Inc.
• Investigators: Study Director: Shrikanta Chattopadhyay, MD, Tscan Therapeutics

Study record dates

Study Major Dates

• Study Start (Estimated): June 18, 2026
• Primary Completion (Estimated): June 1, 2029
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: July 1, 2026
• First Submitted That Met QC Criteria: July 8, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 8, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: AML; MDS; T-cell receptor; Adoptive Cell Therapy; HCT; BMT; T lymphocyte; haploidentical; bone marrow transplant; Hematopoietic cell transplantation; TCR-engineered T cells; HA-2; TSC-101; RIC; allogenic stem cell transplant; Mismatched unrelated donors MMUD; ALLOHA-2
• Other Study ID Numbers: TSCAN-001 (Phase 3)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No